Novavax (NASDAQ: NVAX) and ACADIA Pharmaceuticals (NASDAQ:ACAD) are both medical companies, but which is the superior investment? We will compare the two companies based on the strength of their dividends, valuation, earnings, institutional ownership, analyst recommendations, risk and profitability.
Insider and Institutional Ownership
50.5% of Novavax shares are owned by institutional investors. Comparatively, 97.8% of ACADIA Pharmaceuticals shares are owned by institutional investors. 4.0% of Novavax shares are owned by insiders. Comparatively, 22.3% of ACADIA Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.
Valuation & Earnings
This table compares Novavax and ACADIA Pharmaceuticals’ top-line revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Price/Sales Ratio||EBITDA||Earnings Per Share||Price/Earnings Ratio|
|Novavax||$21.04 million||13.76||-$186.64 million||($0.77)||-1.30|
|ACADIA Pharmaceuticals||$62.99 million||60.65||-$305.32 million||($2.53)||-12.34|
Novavax has higher revenue, but lower earnings than ACADIA Pharmaceuticals. ACADIA Pharmaceuticals is trading at a lower price-to-earnings ratio than Novavax, indicating that it is currently the more affordable of the two stocks.
This table compares Novavax and ACADIA Pharmaceuticals’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Volatility and Risk
Novavax has a beta of 1.94, indicating that its share price is 94% more volatile than the S&P 500. Comparatively, ACADIA Pharmaceuticals has a beta of 3.93, indicating that its share price is 293% more volatile than the S&P 500.
This is a summary of recent recommendations for Novavax and ACADIA Pharmaceuticals, as provided by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Novavax currently has a consensus price target of $5.31, indicating a potential upside of 431.68%. ACADIA Pharmaceuticals has a consensus price target of $44.17, indicating a potential upside of 41.51%. Given Novavax’s higher possible upside, research analysts plainly believe Novavax is more favorable than ACADIA Pharmaceuticals.
ACADIA Pharmaceuticals beats Novavax on 9 of the 13 factors compared between the two stocks.
Novavax Company Profile
Novavax, Inc. is a clinical-stage vaccine company focused on the discovery, development and commercialization of recombinant nanoparticle vaccines and adjuvants. The Company operates through developing recombinant vaccines segment. The Company, through its recombinant nanoparticle vaccine technology, produces vaccine candidates to respond to both known and newly emerging diseases. The Company’s product pipeline focuses on a range of infectious diseases with vaccine candidates in clinical development for respiratory syncytial virus (RSV), seasonal influenza, pandemic influenza and the Ebola virus (EBOV). The Company’s lead adjuvant for human applications, Matrix-M, is in a Phase I/II clinical trial for pandemic influenza H7N9 vaccine candidate. It is also testing Matrix-M in conjunction with its EBOV vaccine candidate in a Phase I clinical trial. It is developing additional pre-clinical stage programs in a range of infectious diseases, including Middle East respiratory syndrome (MERS).
ACADIA Pharmaceuticals Company Profile
ACADIA Pharmaceuticals Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of medicines for central nervous system (CNS) disorders. Its lead drug candidate, NUPLAZID (pimavanserin), is used for the treatment of hallucinations and delusions associated with Parkinson’s disease psychosis (PD Psychosis). NUPLAZID is a selective serotonin inverse agonist (SSIA), preferentially targeting 5-HT2A receptors. The Company is conducting a Phase II trial, referred to as the SERENE Study, designed to examine the efficacy and safety of pimavanserin as a treatment for Alzheimer’s disease (AD) Agitation. It is also conducting a Phase III, six-week, randomized, double-blind, placebo-controlled, multi-center, outpatient study, referred to as the ENHANCE-1 study, designed to examine the use of pimavanserin in patients with schizophrenia.
What are top analysts saying about Novavax Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Novavax Inc. and related companies.